Back to search results

Telephone Coaching for Advance Care Planning in Advanced Cancer

This study is looking at whether telephone-based coaching sessions, called Talking About Cancer (TAC), can help patients with advanced cancer (cancer that has spread) and their support person with advance care planning (ACP). ACP involves talking about end-of-life care and completing documents like living wills. Many patients with advanced cancer don't have these important conversations. The TAC sessions are led by a social worker over the phone. You can join if you are 18 or older, have stage III or IV cancer, speak English or Spanish, and have access to a phone or computer. Your support person can also join if they meet similar criteria. The study will measure how many people enroll, how many complete the sessions, and how acceptable the sessions are to participants. The current recruitment status is unclear.

Study design
This study is an interventional trial with a planned enrollment of 80 participants. Participants will be randomly assigned to either receive two telephone coaching sessions or an advance care planning brochure.
What's involved
If you are in the coaching group, you will attend two 45-60 minute telephone coaching sessions, once a week for two weeks. All participants will also complete surveys.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed up at 6 and 12 weeks after they are randomly assigned to a group.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07141407

Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person

Recruiting
NAAges 18+InterventionalSupportive care
Fred Hutchinson Cancer Center
~80 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:Supportive CareTelephone-Based InterventionSurvey AdministrationEducational Intervention

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Enrollment rate (Feasibility)
Measured over At 6-weeks post-randomization
+3 more outcomes measured

Conditions

Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphatic System Neoplasm

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT07141407

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washingtonstudy coordinator listed

    Recruiting

  • Providence Regional Cancer Partnership

    Everett, Washingtonno site contact published

    Recruiting

  • Skagit Regional Health Cancer Care Center

    Mount Vernon, Washingtonno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Megan Shen, PhD · PRINCIPAL_INVESTIGATOR · Fred Hutch/University of Washington Cancer Consortium

Who to contact

Megan Shen, PhD
[email protected]
206-667-4172
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

PATIENT: Current diagnosis of stage III or IV cancer
PATIENT: Able to provide informed consent
PATIENT: Fluent in English or Spanish
PATIENT: Have access to a telephone, computer, or mobile device
CAREGIVER (SUPPORT PERSON): Person patient indicates provides support
CAREGIVER (SUPPORT PERSON): English or Spanish speaking
CAREGIVER (SUPPORT PERSON): 18 years of age or older
CAREGIVER (SUPPORT PERSON): Able to provide informed consent

Exclusion

PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer)
PATIENT: Receiving hospice at the time of enrollment
PATIENT: Younger than age 18

What this trial measures

  • Enrollment rate (Feasibility)At 6-weeks post-randomization

    Feasibility will be examined using enrollment rates. Feasibility cutoffs will be based on prior research and include the following: ≥ 50% of eligible participants will enroll in the study. Low rates of enrollment, including missing data, will indicate low feasibility.

  • Intervention session completion rate (Feasibility)At 6-weeks post-randomization

    Feasibility will be examined using enrollment and intervention completion rates as outcomes. Feasibility cutoffs will be based on prior research and include the following: ≥ 75% of Talking About Cancer sessions will be delivered with fidelity.

  • Acceptability of Intervention Measure (AIM) score (Acceptability)At 6-weeks post-randomization

    To analyze intervention acceptability, will examine the median score for the AIM measure, with a median of \>= 4 indicating acceptability (on a 5-point Likert scale where 4=Agree and 5=Completely agree and higher scores indicate higher levels of acceptability).

  • Completion rate of study assessments (Feasibility of collecting primary and secondary outcomes)At baseline, 6-weeks post- randomization, and 12-weeks post-randomization

    Feasibility of the study collection procedures will be examined using study-related assessment completion rates and includes the following: ≥ 50% of enrolled patients will adhere to and complete assigned intervention components and study-related assessments.